This is a case-control type of study for women with chronic hypertension, a history of preeclampsia, or maternal cardiac or kidney disease. A care path was designed with reduced visits enhanced with a digital platform for daily blood pressure and symptom monitoring starting from 16 weeks of gestation. Home-measurements were monitored in-hospital by obstetric professionals, taking actions upon alarming results. This prospective SAFE@HOME group was compared to a retrospective control group managed without self-monitoring.
Baseline characteristics of the SAFE@HOME users 103 participants and a control group of 133 individuals were comparable. In the SAFE@HOME group, antenatal visits were lower compared to the control group. Admissions for hypertension or suspected preeclampsia were significantly fewer in the SAFE@HOME group. Telemonitoring participants were highly satisfied using the platform. No differences were observed for maternal and perinatal outcomes.
The findings of this conclude that the care path including blood pressure telemonitoring for women at risk of preeclampsia allows fewer antenatal visits, ultrasounds, and hypertension-related admissions. We observed no differences in perinatal outcomes.
Reference: https://www.sciencedirect.com/science/article/pii/S2210778920300957
